Back to Journals » OncoTargets and Therapy » Volume 7

A new inflammation index is useful for patients with esophageal squamous cell carcinoma

Authors Feng J, Huang Y, Chen Q

Received 21 May 2014

Accepted for publication 21 July 2014

Published 30 September 2014 Volume 2014:7 Pages 1811—1815


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Ji-Feng Feng,1 Ying Huang,2 Qi Xun Chen1

1Department of Thoracic Surgery, 2Department of Operating Theater, Zhejiang Cancer Hospital, Hangzhou, People's Republic of China

Background: The prognostic value of inflammation indexes in esophageal cancer has not been established. Recent studies have shown that the advanced lung cancer inflammation index (ALI) is a useful predictive factor. The purpose of the current study was to determine whether the ALI is useful for predicting long-term survival in patients with esophageal squamous cell carcinoma (ESCC).
Patients and methods: A total of 293 patients who had undergone esophagectomy for ESCC were included. The ALI was calculated as body mass index × serum albumin/neutrophil-to-lymphocyte ratio. Then, patients were divided into two groups: ALI ≥18 and ALI <18. The Kaplan–Meier method was used to calculate the cancer-specific survival (CSS), and the difference was assessed by the log-rank test. Univariate and multivariate analyses were performed to evaluate the prognostic factors.
Results: In our study, there were 120 patients with ALI <18 and 173 patients with ALI ≥18. ALI was significantly higher in patients with large tumors (P=0.028), poor differentiation (P=0.010), deep invasion (P=0.009), and nodal metastasis (P=0.004). The 5-year CSS was 34.5% in our study. Patients with ALI <18 had a significantly poorer 5-year CSS compared to ALI ≥18 (21.7% versus 43.4%, P<0.001). On multivariate analysis, we showed that the ALI was a significant predictive factor of CSS (P=0.024).
Conclusion: The ALI is still a useful predictive factor for long-term CSS in patients with ESCC. However, the prognostic value of the ALI is yet to be formally tested within randomized trials.

Keywords: esophageal squamous cell carcinoma, neutrophil-to-lymphocyte ratio, body mass index, albumin, survival

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]